Search results
Results from the WOW.Com Content Network
The site began in 1998 as a pen and paper questionnaire called the Harvard Cancer Risk Index. [2] In January 2000, The Harvard Cancer Risk Index developed into an online assessment and was renamed Your Cancer Risk, and offered assessments for four cancers: breast, colon, lung, and prostate. Six months later, eight additional cancers were added. [3]
“Every woman should assess her risk for breast cancer, especially if she has dense breasts,” says Gloria A Bachmann, MD, associate dean for women’s health at Rutgers Robert Wood Johnson ...
A Mediterranean diet - with added olive oil - can reduce the risk of breast cancer in women by two-thirds, a study has suggested. The diet, which involves a combination of food groups from ...
Based on her own family history of breast cancer and her breast density, 10 years ago, Berg said that she determined for herself that she had a 19.7% lifetime risk of developing the disease.
For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [28]
Virgin olive oil is a lesser grade of virgin oil, with free acidity of up to 2.0%, and is judged to have a good taste, but may include some sensory defects. Refined olive oil is virgin oil that has been refined using charcoal and other chemical and physical filters, methods which do not alter the glyceridic structure. It has a free acidity ...
The result is a lifetime risk and a five-year risk based on factors that have been tied to a higher risk of breast cancer. For comparison, it also gives an average risk for U.S. women of the same ...
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.